Immune-based Therapies
Paraneoplastic Brachial Amyotrophic Diplegia and Encephalitis With Ma2-IgG During Immune Checkpoint Inhibitor Use for Mesothelioma: A Case Report
JTO Clinical and Research Reports 2026 March 6 [Link] Sanem Pinar Uysal, Shervin Badihian, Karlo Toljan, Nirmal Andrapalliyal, James Stevenson, Jonathan Lee, Amy Kunchok Abstract Background: Immune checkpoint inhibitors (ICIs) improve cancer survival but can cause neurologic immune-related adverse events. Ma2-IgG-associated paraneoplastic neurologic syndrome typically presents with central nervous system involvement in patients with testicular…
Read MoreImmunotherapy resistance and strategies in malignant pleural mesothelioma
Cancer Drug Resistance 2026 March 26 [Link] Wanyi Xia, Yulong Zhang, Juanzhi Zhao, Xiaoli Tan, Shaolong Ju, Wei Zou, Chaoqun Chen, Chunwei Li, Yanghua Xu, Yingming Peng, Shengqiao Li Abstract Malignant pleural mesothelioma (MPM) remains one of the most aggressive thoracic malignancies, characterized by profound resistance to conventional modalities such as surgery, chemotherapy, and radiotherapy,…
Read MoreTumor DNA methylation subtypes predict immunotherapy outcomes in pleural mesothelioma patients in the NIBIT-EPI-MESO study
Nature Genetics 2026 May [Link] Luana Calabrò, Francesca P Caruso, Alessia Covre, Teresa M R Noviello, Maria F Lofiego, Rossella Tufano, Luigi Ferraro, Piera Grisolia, Antonio De Falco, Vincenzo Lagano, Francesco Sgambelluri, Giovanna Sabella, Giulia Rossi, Giulia Gibilisco, Francesco Marzani, Emma Bello, Elena Simonetti, Vincenzo D’Alonzo, Michele Caraglia, Sandra Coral, Antonina De Angelis, Luigi Cerbone,…
Read MoreEmerging Strategies in the Diagnosis and Treatment of Pleural Mesothelioma: An Overview
Thoracic Cancer 2026 April [Link] Raffaella Pagliaro, Beatrice Leonardi, Angela Schiattarella, Grazia Bergameo, Carmine Picone, Adolfo Gallipoli D’Errico, Filippo Scialò, Fabio Perrotta, Maria Luisa De Rimini, Alfonso Fiorelli, Andrea Bianco Abstract Pleural mesothelioma (PM) is a rare and aggressive cancer arising from pleural mesothelial cells with a strong association to asbestos exposure. Among the diagnostic…
Read MoreRegional immunosuppression and associated systemic markers in focally relapsed sarcomatoid mesothelioma: case report
Journal for Immunotherapy of Cancer 2026 April 15 [Link] Hely Ollila, Prateek Kulkarni, Hyojin Kim, Pratiti Ankola, Navin K Chintala, Carlos Thomas, Jennifer L Sauter, Michael Offin, Prasad S Adusumilli Abstract A 52-year-old man presented with sarcomatoid diffuse pleural mesothelioma that had relapsed at an isolated site after a complete response to dual-immune checkpoint inhibition…
Read MoreFrom biology to therapy: current standards and emerging strategies in pleural mesothelioma
Frontiers in Oncology 2026 March 26 [Link] J H L T van Genugten, C J de Gooijer, Paul Baas Abstract Pleural mesothelioma (PM) is an aggressive malignancy with limited therapeutic options and poor long-term prognosis. Platinum-based chemotherapy has been the standard-of-care for most patients for decades. While the decoding of the genomic alterations in PM…
Read MoreRadioimmunotherapy for Malignant Mesothelioma Targeting C-ERC/Mesothelin
Pharmaceuticals 2026 March 18 [Link] Hirofumi Hanaoka, Aiko Yamaguchi, Masahiro Maeda, Tatsuya Segawa, Noboru Oriuchi Abstract Background/Objectives: Malignant mesothelioma has a poor prognosis and limited therapeutic options. C-ERC/mesothelin is highly expressed in mesotheliomas and is a potential target for radioimmunotherapy (RIT). This study evaluated the radiolabeled anti-C-ERC/mesothelin antibody mAb 22A31 as a therapeutic agent. Methods:…
Read MoreCase Report: Immune checkpoint inhibitor-triggered anti-Ma2 paraneoplastic encephalitis in sarcomatoid pleural mesothelioma: a fatal case
Frontiers in Oncology 2026 March 9 [Link] Ilker Nihat Okten, Tuba Baydaş Abstract Background: Neurological immune-related adverse events (N-irAEs) represent rare but potentially fatal complications of immune checkpoint inhibitor (ICI) therapy. Among these, encephalitis associated with paraneoplatic neuronal antibodies poses a major diagnostic and therapeutic challenge, as it blurs the distinction between drug-induced toxicity and…
Read MorePhase 1/1b study of direct intratumoral injection of pleural mesothelioma of immunostimulant prior to surgical resection
The Journal of Thoracic & Cardiovascular Surgery 2026 March 24 [Link] Andrea S Wolf, Shubham Gulati, Komal Dolasia, Bailey Fitzgerald, Jorge Gomez, David Yankelevitz, Andres Salazar, Alexander M Tsankov, Thomas Marron, Raja Flores Abstract Objective: To evaluate the role of neoadjuvant injection of the viral mimic poly-ICLC (polyinosinic-polycytidylic acid-poly-l-lysine carboxymethylcellulose) in patients with pleural mesothelioma…
Read MoreCase Report: Immune checkpoint inhibitor-triggered anti-Ma2 paraneoplastic encephalitis in sarcomatoid pleural mesothelioma: a fatal case
Frontiers in Oncology 2026 March 9 [Link] Ilker Nihat Okten, Tuba Baydaş Abstract Background: Neurological immune-related adverse events (N-irAEs) represent rare but potentially fatal complications of immune checkpoint inhibitor (ICI) therapy. Among these, encephalitis associated with paraneoplatic neuronal antibodies poses a major diagnostic and therapeutic challenge, as it blurs the distinction between drug-induced toxicity and…
Read More
Skip to content